Minerva Neurosciences, Inc (NERV): Price and Financial Metrics


Minerva Neurosciences, Inc (NERV): $3.34

0.02 (+0.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NERV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NERV Stock Price Chart Interactive Chart >

Price chart for NERV

NERV Price/Volume Stats

Current price $3.34 52-week high $15.27
Prev. close $3.32 52-week low $2.51
Day low $3.26 Volume 19,300
Day high $3.43 Avg. volume 1,684,263
50-day MA $5.87 Dividend yield N/A
200-day MA $5.18 Market Cap 17.84M

Minerva Neurosciences, Inc (NERV) Company Bio


Minerva Neurosciences, Inc. focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company was founded in 2007 and is based in Waltham, Massachusetts.


NERV Latest News Stream


Event/Time News Detail
Loading, please wait...

NERV Latest Social Stream


Loading social stream, please wait...

View Full NERV Social Stream

Latest NERV News From Around the Web

Below are the latest news stories about MINERVA NEUROSCIENCES INC that investors may wish to consider to help them evaluate NERV as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: GlycoMimetics (GLYC) and Minerva Neurosciences (NERV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GlycoMimetics (GLYC – Research Report) and Minerva Neurosciences (NERV – Research Report). GlycoMimetics (GLYC) H.C. Wainwright analyst Edward White maintained a Buy rating on GlycoMimetics today and set a price target of $13.00. The company's shares closed last Wednesday at $0.76, close to its 52-week low of $0.51. According to TipRanks.

Catie Powers on TipRanks | November 9, 2022

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Company To Host Live Webcast Today at 8:30 a.m. ET Company To Host Live Webcast Today at 8:30 a.m. ET

GlobeNewswire | November 9, 2022

Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript

Minerva Neurosciences, Inc. (NASDAQ:NASDAQ:NERV) Q3 2022 Earnings Conference Call November 9, 2022 08:30 AM ET Company Participants Geoff Race - President Remy Luthringer - CEO Frederick…

Seeking Alpha | November 9, 2022

Minerva Neurosciences GAAP EPS of -$1.29 beats by $0.03

Minerva Neurosciences press release (NERV): Q3 GAAP EPS of -$1.29 beats by $0.03.Cash, cash equivalents and restricted cash as of September 30, 2022 were approximately $40.3…

Seeking Alpha | November 9, 2022

Minerva Neurosciences, Inc: Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

Company To Host Live Webcast Today at 8:30 a.m. ETBURLINGTON, Mass., Nov. 09, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central…

Finanz Nachrichten | November 9, 2022

Read More 'NERV' Stories Here

NERV Price Returns

1-mo 26.04%
3-mo -65.50%
6-mo 2.35%
1-year -57.00%
3-year -93.32%
5-year -92.48%
YTD -47.88%
2021 -65.77%
2020 -67.09%
2019 5.49%
2018 11.40%
2017 -48.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8048 seconds.